Found 185 results in Expert Content

In this webinar, participants will learn about a comprehensive strategy to streamline development and derisk clinical studies. Experts will focus on the importance of physiologically based pharmacokinetic (PBPK) modeling, formulation, and technology expertise while sparing API and managing funding and timeline challenges.

Summary: This executive summary showcases critical considerations and strategies for dosing lipid formulations in preclinical models, along with an overview of the regulatory and technical nuances involved in advancing preclinical lipid-based formulations (LBF) to viable clinical dosage forms.

Summary: In this interview with Pharmtech, Karunakar Sukuru, Global Vice President, Rx Product Development, Pharma and Consumer Health, Catalent shares his thoughts on the key benefits of Lipid based formulations (LBF.)

Summary: This executive summary showcases examples of real-life tactical and operational decisions involved in the integrated approach to drug development.

Summary: Download this fact sheet to learn more about our experience and expertise with nitrosamines testing.

Summary: Catalent’s Nottingham facility specializes in early phase development of small molecule drug candidates and complex molecules from bench to clinic through integrated offerings such as...

Summary: In this webinar, experts will discuss the advantages of LBFs and softgels while addressing the ongoing challenges in realizing their full clinical and commercial potential.

Industry experts discuss how QbD strategies can be applied in the systematic evaluation of small batches of spray-dried solid dispersions for oral delivery.

Summary: Download this article to gain insights into the perceived barriers to developing LBFs and recent advances in translating them into useful clinical and commercial products of lipophilic drugs.

During this webinar, industry experts will teach valuable insights, strategies, and practical knowledge to overcome the challenges and pave a successful path to orphan drug development and commercialization.